Utilization of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitor Drugs: A Descriptive Analysis

    Basic Details
    Date Posted
    Monday, July 11, 2022
    Status
    Complete
    Medical Product
    obesity drugs
    sodium-glucose co-transporter-2 (SGLT-2) inhibitor
    Description

    This report presents incidence and counts of 11 generic names contained in the National Drug Code (NDC) directory. Results include total and incident counts of dispensing of the selected drugs (generic names) among enrolled members in the Sentinel Distributed Database (SDD) from 2008 - 2017. Counts and incidence are calculated with 90-day, 180-day, and 270-day washout periods. Results are stratified by year.

    The study period includes data from January 1, 2000 to August 31, 2018. We distributed this request to 17 Sentinel Data Partners on May 17, 2019.

     

    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2000 - August 31, 2018
    Study Type
    Summary Table
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals
    Data Sources
    Sentinel Distributed Database (SDD)